Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01372150 · ClinicalTrials.gov registry record · Phase 3
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
NCT01372150 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 340 participants.
The verdict
NCT01372150, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
Study Summary
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
Interventions
- DRUG placebo
- DRUG fluoxetine
- DRUG desvenlafaxine succinate sustained release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2011-11-17 |
| Est. Completion | 2015-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01372150
The ClinicalTrials.gov registry entry for NCT01372150 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01372150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01372150 about?
NCT01372150 is a clinical study titled "A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD". This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
What is the current status of trial NCT01372150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2011-11-17. Estimated completion is 2015-03-20.
What interventions are being tested in trial NCT01372150?
The interventions under investigation include: placebo (DRUG), fluoxetine (DRUG), desvenlafaxine succinate sustained release (DRUG).
Who is sponsoring clinical trial NCT01372150?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.